312611-92-0 Usage
Description
VK-28 is a chemical compound with demonstrated neuroprotective properties, characterized by its antioxidant and anti-inflammatory effects in animal models of neurological disorders. It also exhibits the potential to regulate dopamine levels in the brain, positioning it as a promising candidate for the development of treatments targeting neurodegenerative diseases such as Parkinson's and Alzheimer's. Further research is essential to elucidate the compound's mechanisms of action and its full therapeutic potential.
Uses
Used in Pharmaceutical Industry:
VK-28 is used as a neuroprotective agent for its potential to mitigate the effects of oxidative stress and inflammation, which are key contributors to neurodegenerative diseases. Its antioxidant and anti-inflammatory properties make it a valuable asset in the development of treatments for conditions like Parkinson's and Alzheimer's.
Used in Neurodegenerative Disease Research:
VK-28 is utilized as a research tool to investigate the underlying mechanisms of neuroprotection, particularly in the context of its ability to regulate dopamine levels in the brain. This research is crucial for advancing our understanding of the compound's therapeutic applications and its potential role in the treatment of neurodegenerative disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 312611-92-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,1,2,6,1 and 1 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 312611-92:
(8*3)+(7*1)+(6*2)+(5*6)+(4*1)+(3*1)+(2*9)+(1*2)=100
100 % 10 = 0
So 312611-92-0 is a valid CAS Registry Number.
312611-92-0Relevant articles and documents
Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators
-
Page/Page column 12, (2010/02/10)
Use of a compound of formula (I), wherein R1 is H or hydrocarbyl; R2 is a hydrophobic radical; R3 is 3-(C2-C6)acyl-4-hydroxyphenyl, 3-hydroxyimino (C2-C6)-alkyl-4-hydroxyphenyl, or COOZ, wherein Z is H, (C1-C6) alkyl, aryl, aryl or ar(C1-C6) alkyl; and n is 1-20; and of a compound of formula (II), wherein R4 is (C1-C6) alkyl, cyano (C1-C6) alkyl, (C1-C6) alkoxy (C1-C6) alkyl or —CH2NR7R8, wherein R7 and R8, the same or different, is each H or (C1-C6) alkyl, or together with the N atom form a saturated or unsaturated 5-7 membered ring optionally containing a further heteroatom selected from N, O or S, the further N atom being optionally substituted, and either R5 is H and R6 is (C2-C6) acyl or hydroxyimino (C2-C6) alkyl, or R5 and R6 together with the phenyl ring form a quinoline, a 1,2,3,4-tetrahydroquinoline or a perhydroquinoline ring, for the preparation of pharmaceutical compositions for the treatment of Parkinson's disease or stroke.
